Immunitybio, INC 10-Q quarterly reports

ImmunityBio, Inc. reported Q2 2026 results showing significant revenue growth but also substantial net losses and increased liabilities, alongside ongoing legal matters.

ImmunityBio, Inc. has filed its 2025 Equity Incentive Plan, detailing provisions for stock options, restricted stock units, and performance awards to attract and retain key personnel.

ImmunityBio reports significant product revenue growth driven by ANKTIVA sales, strengthens cash position through equity offerings, and advances its clinical pipeline despite ongoing net losses and regulatory challenges.

ImmunityBio reports significant Q2 2025 revenue growth driven by ANKTIVA sales and secures UK marketing authorization, while navigating ongoing regulatory and financial challenges.

ImmunityBio's Q1 2025 shows increased ANKTIVA sales but ongoing losses and a mixed regulatory outlook.

ImmunityBio reports its Q3 2024 results, highlighting the start of ANKTIVA sales and ongoing clinical development.

ImmunityBio reports its Q2 2024 results, highlighting the start of ANKTIVA commercialization and ongoing clinical development programs.

ImmunityBio's Q1 2024 results show a net loss of $134.1 million, but the company achieved a significant milestone with FDA approval of ANKTIVA.